Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc ≥ 1, or higher?

Thrombosis and Haemostasis

Volumn 113, Issue 6, 2015, Pages 1165-1169

  Olesen, Jonas Bjerring ^a   Torp Pedersen, Christian ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; APIXABAN; DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CLINICAL DECISION MAKING; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; HAZARD RATIO; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; THROMBOEMBOLISM; BLEEDING; CHEMICALLY INDUCED; COMPLICATION; DECISION SUPPORT SYSTEM; EVIDENCE BASED MEDICINE; PATIENT SELECTION; PREDICTIVE VALUE; RISK ASSESSMENT; STROKE; TIME FACTOR; TREATMENT OUTCOME;

ANTICOAGULANTS; ATRIAL FIBRILLATION; DECISION SUPPORT TECHNIQUES; EVIDENCE-BASED MEDICINE; HEMORRHAGE; HUMANS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84931262679     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-02-0154     Document Type: Article

References (34)

1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857–867.
2. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet 2014; 383: 955–962.
3. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidencebased clinical practice guidelines. Chest 2012; 141: e531S-575S.
4. Verma A, Cairns JA, Mitchell LB, et al., Committee CCSAFG. 2014 focused update of the canadian cardiovascular society guidelines for the management of atrial fibrillation. Can J Cardiol 2014; 30: 1114–1130.
5. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the esc guidelines for the management of atrial fibrillation: An update of the 2010 esc guidelines for the management of atrial fibrillation-- developed with the special contribution of the european heart rhythm association. Europace 2012; 14: 1385–1413.
6. Gallego P, Roldan V, Marin F, et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013; 110: 1189–1198.
7. De Caterina R, Husted S, Wallentin L, et al. Vitamin k antagonists in heart disease: Current status and perspectives (section iii). Position paper of the esc working group on thrombosis--task force on anticoagulants in heart disease. Thromb Haemost 2013; 110: 1087–1107.
8. Suzuki S, Yamashita T, Okumura K, et al. Incidence of ischaemic stroke in japanese patients with atrial fibrillation not receiving anticoagulation therapy. Circ J 2014; Epub ahead of print.
9. Okumura K, Inoue H, Atarashi H, et al., Investigators JRR. Validation of cha(2)ds(2)-vasc and has-bled scores in japanese patients with nonvalvular atrial fibrillation: An analysis of the j-rhythm registry. Circ J 2014; 78: 1593–1599.
10. Singer DE, Chang Y, Borowsky LH, et al. A new risk scheme to predict ischaemic stroke and other thromboembolism in atrial fibrillation: The atria study stroke risk score. J Am Heart Assoc 2013; 2: e000250.
11. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891.
12. Petersen P, Boysen G, Godtfredsen J, et al. Placebo- controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The copenhagen afasak study. Lancet 1989; 1: 175–179.
13. Connolly SJ, Laupacis A, Gent M, et al. Canadian atrial fibrillation anticoagulation (cafa) study. J Am Coll Cardiol 1991; 18: 349–355.
14. Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (atria) study. Ann Intern Med 1999; 131: 927–934.
15. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The framingham heart study. J Am Med Assoc 2003; 290: 1049–1056.
16. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: Results from the national registry of atrial fibrillation. J Am Med Assoc 2001; 285: 2864–2870.
17. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study. Br Med J 2011; 342: d124.
18. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The swedish atrial fibrillation cohort study. Eur Heart J 2012; 33: 1500–1510.
19. Mikkelsen AP, Lindhardsen J, Lip GY, et al. Female sex as a risk factor for stroke in atrial fibrillation: A nationwide cohort study. J Thromb Haemost 2012; 10: 1745–1751.
20. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 2010; 137: 263–272.
21. Eckman MH, Singer DE, Rosand J, et al. Moving the tipping point: The decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2011; 4: 14–21.
22. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: A report from the swedish atrial fibrillation cohort study. Circulation 2012; 125: 2298–2307.
23. Friberg L, Skeppholm M, Terent A. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a cha2ds2-vasc score of 1. J Am Coll Cardiol 2015; 65: 225–232.
24. Olson KL, Wood MD, Delate T, et al. Positive predictive values of icd-9 codes to identify patients with stroke or tia. Am J Manag Care 2014; 20: e27–34.
25. Andersen LV, Lip GY, Lindholt JS, et al. Upper limb arterial thromboembolism: A systematic review on incidence, risk factors, and prognosis, including a meta-analysis of risk-modifying drugs. J Thromb Haemost 2013; 11: 836–844.
26. Friberg L, Rosenqvist M. Cardiovascular hospitalization as a surrogate endpoint for mortality in studies of atrial fibrillation: Report from the stockholm cohort study of atrial fibrillation. Europace 2011; 13: 626–633.
27. Friberg J, Buch P, Scharling H, et al. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003; 14: 666–672.
28. Singer DE, Ezekowitz MD. Adding rigor to stroke risk prediction in atrial fibrillation. J Am Coll Cardiol 2015; 65: 233–235.
29. Chao TF, Liu CJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional risk factor of the cha2ds2-vasc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol 2015; 65: 635–642.
30. Huang D, Anguo L, Yue WS, et al. Refinement of ischaemic stroke risk in patients with atrial fibrillation and cha2 ds2 -vasc score of 1. Pacing Clin Electrophysiol 2014; 37: 1442–1447.
31. Lane DA, Lip GY. Patient’s values and preferences for stroke prevention in atrial fibrillation: Balancing stroke and bleeding risk with oral anticoagulation. Thromb Haemost 2014; 111: 381–383.
32. Lahaye S, Regpala S, Lacombe S, et al. Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost 2014; 111: 465–473.
33. Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am J Med 2010; 123: 638–645 e634.
34. Le Heuzey JY, Ammentorp B, Darius H, et al. Differences among western european countries in anticoagulation management of atrial fibrillation. Data from the prefer in af registry. Thromb Haemost 2014; 111: 833–841.